Featured Publications
Towards understanding and predicting suicidality in women: biomarkers and clinical risk assessment
Levey DF, Niculescu EM, Le-Niculescu H, Dainton HL, Phalen PL, Ladd TB, Weber H, Belanger E, Graham DL, Khan FN, Vanipenta NP, Stage EC, Ballew A, Yard M, Gelbart T, Shekhar A, Schork NJ, Kurian SM, Sandusky GE, Salomon DR, Niculescu AB. Towards understanding and predicting suicidality in women: biomarkers and clinical risk assessment. Molecular Psychiatry 2016, 21: 768-785. PMID: 27046645, DOI: 10.1038/mp.2016.31.Peer-Reviewed Original ResearchConceptsFuture hospitalizationConvergent functional genomics approachSuicide completersPrimary end pointSingle blood biomarkerTop biomarkersReceiver-operating characteristic areaRisk prediction scoreClinical risk assessmentDisorder participantsIndependent test cohortForm of APPProphylactic benefitNeurotrophic effectsBlood biomarkersSleep abnormalitiesPsychiatric hospitalizationHospitalizationMood disordersTest cohortCandidate biomarkersSuicide completionSuicidal ideationDrug lithiumChronic stress
2023
Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
Roseberry K, Le-Niculescu H, Levey D, Bhagar R, Soe K, Rogers J, Palkowitz S, Pina N, Anastasiadis W, Gill S, Kurian S, Shekhar A, Niculescu A. Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry 2023, 28: 2894-2912. PMID: 36878964, PMCID: PMC10615756, DOI: 10.1038/s41380-023-01998-0.Peer-Reviewed Original ResearchConceptsIndependent cohortCandidate biomarkersPsychiatric subjectsPersonalized approachConvergent functional genomics approachAnxiety disordersBest overall evidenceAdverse life eventsClinical worseningGene expression signaturesBlood biomarkersAnxiety medicationClinical utilityPsychiatric disordersHigh anxiety stateSevere anxietyUntreated anxietyDecrease qualityIndividual biomarkersAddiction potentialBiomarkersTop biomarkersAnxiety statesRisk predictionExpression signatures
2021
Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
Le-Niculescu H, Roseberry K, Gill SS, Levey DF, Phalen PL, Mullen J, Williams A, Bhairo S, Voegtline T, Davis H, Shekhar A, Kurian SM, Niculescu AB. Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry 2021, 26: 2776-2804. PMID: 33828235, PMCID: PMC8505261, DOI: 10.1038/s41380-021-01061-w.Peer-Reviewed Original ResearchConceptsBlood gene expression biomarkersTop candidate biomarkersMood disordersIndependent cohortStrongest overall evidenceBlood testsTop biomarkersGene expression biomarkersCandidate biomarkersConvergent functional genomics approachMood statesPotential new antidepressantsPsychiatric disorder patientsOverall evidenceVisual analog scaleSimple visual analog scaleMatching of patientsPanel of biomarkersPrecision medicineMonitoring of responseBipolar mood disorderExpression biomarkersCell differentiation functionsObjective assessmentSevere mania
2017
Precision medicine for suicidality: from universality to subtypes and personalization
Niculescu A, Le-Niculescu H, Levey D, Phalen P, Dainton H, Roseberry K, Niculescu E, Niezer J, Williams A, Graham D, Jones T, Venugopal V, Ballew A, Yard M, Gelbart T, Kurian S, Shekhar A, Schork N, Sandusky G, Salomon D. Precision medicine for suicidality: from universality to subtypes and personalization. Molecular Psychiatry 2017, 22: 1250-1273. PMID: 28809398, PMCID: PMC5582166, DOI: 10.1038/mp.2017.128.Peer-Reviewed Original ResearchConceptsSuicidal ideationIndependent cohortPersonalized approachFuture hospitalizationPsychiatric diagnosisCandidate biomarkersUniversal biomarkerBlood gene expression biomarkersBiology of suicideTop biomarkersNovel predictive biomarkerHigh-risk groupNon-psychiatric disordersDrug repurposing analysisPublic health problemMonitoring of responseNovel potential therapeuticsHigher suicidal ideationPredictive biomarkersClinical trialsComprehensive stepwise approachRisk groupsLarge cohortMood disordersPreventive therapeutics
2015
Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach
Niculescu AB, Levey DF, Phalen PL, Le-Niculescu H, Dainton HD, Jain N, Belanger E, James A, George S, Weber H, Graham DL, Schweitzer R, Ladd TB, Learman R, Niculescu EM, Vanipenta NP, Khan FN, Mullen J, Shankar G, Cook S, Humbert C, Ballew A, Yard M, Gelbart T, Shekhar A, Schork NJ, Kurian SM, Sandusky GE, Salomon DR. Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach. Molecular Psychiatry 2015, 20: 1266-1285. PMID: 26283638, PMCID: PMC4759104, DOI: 10.1038/mp.2015.112.Peer-Reviewed Original ResearchConceptsFuture hospitalizationPsychiatric diagnosisSuicidal ideationCandidate biomarkersBipolar disorderPsychiatric participantsBlood gene expression biomarkersSuicidal behaviorConvergent functional genomics approachSuicide completersPreventive lifestyle modificationsTop candidate biomarkersTop biomarkersAcute panic attacksPotential therapeutic targetBipolar disorder participantsMajor psychiatric disordersIndependent test cohortSuicide risk factorsThoughts of suicideLifestyle modificationAcute suicidalityRisk factorsInflammatory responsePsychological stress responses